Results 121 to 130 of about 2,487,415 (296)

CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer

, 2019
Jiansong Wang,1 Wencheng Che,2 Weimin Wang,1 Gongzhang Su,3 Tianchang Zhen,3 Zhongmin Jiang31Graduate Department, Weifang Medical University, Weifang, Shandong 261031, People’s Republic of China; 2Department of Thoracic Surgery, Zibo Central ...
Jiang Z, Zhen T, Che W, Wang W, Wang J, Su G   +5 more
core  

Cisplatin resistance and opportunities for precision medicine

Pharmacological Research, 2016
Cisplatin is one of the most commonly used chemotherapy drugs, treating a wide range of cancer types. Unfortunately, many cancers initially respond to platinum treatment but when the tumor returns, drug resistance frequently occurs. Resistance to cisplatin is attributed to three molecular mechanisms: increased DNA repair, altered cellular accumulation,
openaire   +2 more sources

Activation of Metal Complexes With Ultrasound Waves for Targeted Anticancer Therapy

Angewandte Chemie International Edition, EarlyView.
Ultrasound enables non‐invasive activation of metal‐based therapeutics deep within tumors. Acoustic cavitation can drive sonodynamic reactive oxygen species generation or mechanochemical metal–ligand bond dissociation, enabling controlled release of bioactive payloads.
Félix Grosjean, Nicolás Montesdeoca, Gilles Berger, Johannes Karges   +3 more
wiley   +1 more source

Cisplatin resistance coupled to enhanced sensitivity to metabolic interventions

, 2018
Specific metabolic alterations have recently been observed in cisplatin-resistant cancers. As a result, cisplatin resistance can be overcome by co-administration of pyridoxine, and cisplatin-resistant cancer cells become exquisitely sensitive to killing ...
Maria Castedo, Obrist, Florine, Florine Obrist, Guido Kroemer, Castedo, Maria, Kroemer, Guido   +5 more
core   +1 more source

MiR-21-5p Modulates Cisplatin-Resistance of CD44+ Gastric Cancer Stem Cells Through Regulating the TGF-β2/SMAD Signaling Pathway [PDF]

Xinyang Nie,1– 3,* Jian Liu,1,2,* Daohan Wang,1,2,* Chuan Li,1,2 Yuxin Teng,1,2 Zhufeng Li,1,2 Yangpu Jia,1,2 Peiyao Wang,1,2 Jingyu Deng,2,3 Weidong Li,1,2 Li Lu1,2 1Department of General Surgery, Tianjin Medical University General Hospital,
Li W, Lu L, Liu J, Li Z, Wang P, Li C, Wang D, Jia Y, Deng J, Teng Y, Nie X   +10 more
core  

Resistance profile of IGROVCDDP to cisplatin and ouabain.

, 2013
Resistance profile of IGROVCDDP to cisplatin and ouabain.
Britta Stordal (202537), Sandra Roche (316367), Jean-Pierre Gillet (316368), Martin Clynes (41732), Victoria McEneaney (202543), Michael Gottesman (316369), Marion Hamon (316366), John J. O’Leary (288259)   +7 more
core   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu, Zeynep Betül Sarı, Muhammed Emin Sarı, Erdi Can Aytar   +3 more
wiley   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Targeting ferroptosis as a potential strategy to overcome the resistance of cisplatin in oral squamous cell carcinoma

Frontiers in Pharmacology
Oral squamous cell carcinoma (OSCC) is a crucial public health problem, accounting for approximately 2% of all cancers globally and 90% of oral malignancies over the world.
Rongkun Chen, Rongkun Chen, Shuyu Zhu, Ruoyu Zhao, Ruoyu Zhao, Wang Liu, Wang Liu, Luxin Jin, Luxin Jin, Xiaobin Ren, Xiaobin Ren, Hongbing He   +11 more
doaj   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source